Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Center, Randomized, Open-label, Two-arm, Parallel Design Study to Evaluate PK and Safety Profile of Multiple Ascending Oral Doses of Separately Using TG-2349 or DAG181 or TG-2349 Plus DAG181 in Healthy Chinese Volunteers

NCT03610880 is registered in ClinicalTrials.gov with Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT03610880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03610880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Center, Randomized, Open-label, Two-arm, Parallel Design Study to Evaluate PK and Safety Profile of Multiple Ascending Oral Doses of Separately Using TG-2349 or DAG181 or TG-2349 Plus DAG181 in Healthy Chinese Volunteers
Lead sponsor
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
October 17, 2017
Completion date
February 5, 2018
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy chinese volunteers